4369 — Tri Chemical Laboratories Income Statement
0.000.00%
- ¥83bn
- ¥76bn
- ¥19bn
- 96
- 25
- 39
- 55
Annual income statement for Tri Chemical Laboratories, fiscal year end - January 31st, JPY millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,802 | 11,574 | 13,803 | 11,246 | 18,906 |
Cost of Revenue | |||||
Gross Profit | 4,381 | 4,835 | 5,579 | 4,086 | 8,012 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,130 | 8,615 | 10,299 | 9,323 | 13,649 |
Operating Profit | 2,672 | 2,959 | 3,505 | 1,923 | 5,256 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,323 | 5,295 | 6,187 | 3,277 | 6,583 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,377 | 4,095 | 4,832 | 2,471 | 4,962 |
Net Income Before Extraordinary Items | |||||
Net Income | 3,377 | 4,095 | 4,832 | 2,471 | 4,962 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,377 | 4,095 | 4,832 | 2,471 | 4,962 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 109 | 127 | 149 | 76.6 | 153 |
Dividends per Share |